首页AutophagyEpigenetic Reader Domain
Epigenetic Reader Domain
T0808 Diflunisal Diflunisal is a cyclooxygenase (COX) Inhibitor, used as an anti-inflammatory analgesic.
T10520 BET-IN-2 BET-IN-2 is a BET inhibitor (IC50: 52 nM for BRD4-BD1).
T10521 BET-IN-4 BET-IN-4 is a potent BRD4 inhibitor (IC50 ≤ 1 μM).
T10522 BET-IN-6 BET-IN-6 is an effective and high-affinity inhibitor of BRD2/BRD4. It is the ligand for target protein BRD2/4 and is used for the synthesis of PROTAC BRD2/BRD4 degrader-1.
T10641 C-82 C-82 is a specific CBP/β-catenin antagonist. It inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300.
T10702 CBP/EP300-IN-2 CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc) extracted from patent WO2017205538A1 (example 25).
T10717 CBP-IN-1 CBP-IN-1 is a potent inhibitor of p300/CBP bromodomain.
T10773 CF53 CF53 is a highly potent, selective, and orally active inhibitor of BET protein (Ki: <1 nM, Kd: 2.2 nM, IC50: 2 nM for BRD4 BD1).
T10879 CPI-0610 carboxylic acid CPI-0610 carboxylic acid is a ligand for target protein for PROTAC. It is a potent bromodomain and extra-terminal (BET) protein inhibitor with the potential in the therapy of multi
T11136 E-7386 E-7386 is an oral active CBP/ -catenin modulator.
T11291 FKBP12 PROTAC dTAG-13 FKBP12 PROTAC dTAG-13 (dTAG-13) is a degrader of FKBP12F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 (dTAG-13) also is a selective
T11292 FKBP12 PROTAC dTAG-7 FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN. FKBP12
T11441 GNE-987 GNE-987 is a highly active chimeric BET degrader. GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50: 4.7 and 4.4 nM, respective
T11563 Histone Acetyltransferase Inhibitor II Histone Acetyltransferase Inhibitor II is a selective and cell permeable inhibitor of p300 histone acetyltransferase(IC50 : 5 µM).with anti-acetylase activity in mammalian cells.
T11597 IACS-9571 IACS-9571 is a selective and potent inhibitor of TRIM24 and BRPF1, (IC50: 8 nM for TRIM24; Kds: 31 nM and 14 nM for TRIM24 and BRPF1).
T11597L IACS-9571 Hydrochloride IACS-9571 Hydrochloride is a selective and potent inhibitor of TRIM24 and BRPF1, (IC50: 8 nM for TRIM24; Kds: 31 nM and 14 nM for TRIM24 and BRPF1).
T11887 LT052 LT052 shows nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2. LT052 has inhibitory activities against BRPF1b (IC50=567.5 nM). LT052 has anti-inflammatory activity.
T12112 MS402 MS402 is a novel BD1-selective BET BrD inhibitor.
T12113 MS645 MS645 is an inhibitor of bivalent BET bromodomains (BrD) (Ki of 18.4 nM for BRD4-BD1/BD2).
T12338 OXFBD04 OXFBD04 is a potent and selective inhibitor of BRD4(IC50 of 166 nM).
T12346 P300/CBP-IN-5 P300/CBP-IN-5 is a potent inhibitor of p300/CBP histone acetyltransferase (IC50 of 18.8 nM).
T12513 PNZ5 PNZ5 is a potent and isoxazole-based pan-BET inhibitor, with high selectivity and potency similar to the well-established (+)-JQ1, with a KD of 5.43 nM for BRD4(1).
T12560 PROTAC BRD9 Degrader-1 PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader with IC50 of 13.5 nM.
T12660 (Rac)-BAY1238097 (Rac)-BAY1238097 is a inhibitor of BET(IC50 of 1.02 μM for BRD4),used in cancer research.
T12660L BAY1238097 BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different MM (multiple myeloma) and AML (acute myeloid leuke
T12798 (S)-GNE-987 (S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC).
T13086 I-BET762 carboxylic acid I-BET762 carboxylic acid is an inhibitor of BRD4(pIC50 of 5.1).
T13105 TD-428 TD-428 is a highly specific degrader of BRD4(DC50 of 0.32 nM). TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficien
T13190 TP-472 TP-472 is a selective inhibitor of BRD9 (Kd: 33 nM).
T13366 YHO-13351 YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific BCRP inhibitor.
T13396 Zinc Protoporphyrin Zinc Protoporphyrin is an orally active and competitive inhibitor of heme oxygenase-1 (HO-1) and markedly attenuates the protective effects of Phloroglucinol (PG) against H2O2, and
T13397 ZINC03129319 ZINC03129319 is an inhibitor of dengue virus (DENV) NS2B-NS3 protease,and has inhibition constants (Ki1) of 92 μM and Ki3 of 20 μM.
T13412 ZM223 ZM223 is a potent non-covalent inhibitor of NEDD8 activating enzyme (NAE).
T13715 GSK9311 hydrochloride GSK9311 hydrochloride, a less active analog of GSK6853, can be used as a negative control. GSK9311 hydrochloride inhibits BRPF bromodomain (pIC50s: 6.0 and 4.3 for BRPF1 and BRPF2)
T13715L GSK9311 GSK9311 inhibits BRPF bromodomain (pIC50: 6.0 and 4.3 for BRPF1 and BRPF2, respectively). GSK9311 is a less active analog of GSK6853. It can be used as a negative control.
T13785 MZP-54 MZP-54 is a selective degrader of BRD3/4 based on PROTAC technology(Kd of 4 nM for Brd4BD2)
T13786 MZP-55 MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)
T13833 PROTAC BRD4 Degrader-1 PROTAC BRD4 Degrader-1 is an efficacious degrader of BRD4(BRD4 BD1,IC50 of 41.8 nM).
T13834 PROTAC BRD4 Degrader-2 PROTAC BRD4 Degrader-2 is an efficacious degrader of PROTAC BRD4(BRD4 BD1,IC50 of 14.2 nM).
T13835 PROTAC BRD4 Degrader-3 PROTAC BRD4 Degrader-3 is an efficacious degrader of PROTAC BRD4.
T13848 SMARCA-BD ligand 1 for Protac SMARCA-BD ligand 1 for Protac is a compound capable of binding to SMARCA2, the BAF ATPase subunit, based on the Protac technology for degrading SMARCA2
T13849 PROTAC BET Degrader-1 PROTAC BET Degrader-1 is a potent degrader of BET based on PROTAC.
T13850 PROTAC BET degrader-3 PROTAC BET Degrader-3 is a potent degrader OF BET based on PROTAC.
T13890 SMARCA-BD ligand 1 for Protac dihydrochloride SMARCA-BD ligand 1 for Protac dihydrochloride binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
T13915 PROTAC BRD9-binding moiety 1 PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.
T13977 (R)-UT-155 (R)-UT-155 is a selective androgen receptor degrader (SARD) ligand.
T14073 A-485 A-485 is a potent and selective catalytic p300/CBP inhibitor(IC50s of 9.8 nM and 2.6 nM for p300 and CBP, respectively).
T14512 BAZ2-ICR BAZ2-ICR is an epigenetic chemical probe and it also is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds o
T14550 BETd-260 BETd-260 is a potent degrader of BET based on PROTAC technology, with as low as 30 pM against BRD4 protein in RS4;11 leukemia cell line.
T14685 BMS-986158 BMS-986158 is a potent BET inhibitor. With IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respect
T14776 BRD4 Inhibitor-10 BRD4 Inhibitor-10 is an inhibitor of BRD4-BD1 (IC50: 8 nM).
T15014 CTPB CTPB is a p300 histone acetyltransferase (HAT) enzyme activator.
T1516 Curcumin Curcumin is a phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties. Curcumin blocks the formation
T15216 EML 425 EML 425 is a potent and selective inhibitor of CREB binding protein (CBP)/p300 (IC50s: 2.9 and 1.1 μM, respectively).
T15397 GNE-049 GNE-049 is a highly potent and selective inhibitor of CBP (IC50: 1.1 nM in TR-FRET assay). GNE-049 also inhibits BRET and BRD4(1) (IC50s: 12 nM and 4200 nM, respectively).
T15399 GNE-207 GNE-207 is a selective and orally bioavailable inhibitor of the bromodomain of CBP (IC50: 1 nM). It has a selective index of >2500-fold against BRD4 (1). GNE-207 displays excelle
T15400 GNE-272 GNE-272 is a selective inhibitor of CBP/EP300 (IC50: 0.02, 0.03, and 13 μM for CBP, EP300, and BRD4, respectively) and a selective in vivo probe for CBP/EP300.
T15405 GNE-781 GNE-781 is a highly potent and selective inhibitor of CBP (IC50: 0.94 nM in TR-FRET assay). GNE-781 also inhibits BRET and BRD4(1) (IC50s: 6.2 nM and 5100 nM, respectively).
T15419 GS-626510 GS-626510 is an orally bioavailable inhibitor of BET family bromodomains (Kd: 0.59-3.2 nM for BRD2/3/4; IC50: 83 nM and 78 nM for BD1 and BD2).
T15441 GSK8573 GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
T15443 GSK8814 GSK8814 is a selective and ATAD2/2B bromodomain chemical probe and inhibitor (binding constant pKd=8.1 and a pKi=8.9 in BROMOscan). GSK8814 displays 500-fold selectivity for ATAD2
T15484 HJB97 HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity. HJB97 is a high-affinity inhibitor of BET (Kis: 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2
T15794 LUT014 LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
T16139 MRS2698 MRS2698 is an effective and highly selective agonist of the P2Y2 receptor (EC50: 8 nM). MRS2698 also is >300-fold P2Y2-selective versus the P2Y4 and P2Y6 receptors.
T16154 MS417 MS417 is an inhibitor of BET-specific BRD4(BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM, respectively), with weak selectivity at CBP BRD with IC50 of 32.7
T17147 TPOP146 TPOP146 is a selective CBP/P300 benzoxazepine bromodomain inhibitor (Kd: 134 nM and 5.02 μM for CBP and BRD4).
T17249 VZ185 VZ185 is an effective and selective dual BRD7/9 PROTAC degrader (DC50s: 4.5 and 1.8 nM, respectively).
T17294 ZL0454 ZL0454 is an effective and selective Bromodomain-containing protein 4 inhibitors (IC50: 49 and 32 nM for BD1 and BD2).
T17297 ZXH-3-26 ZXH-3-26 is a selective degrader of the PROTAC BRD4 (DC50/5h: ~ 5 nM).
T17311 (+)-JQ1 PA (+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal (BET) inhibitor JQ1(IC50 of 10.4 nM).
T1854 MS436 MS436 is a selective, small-molecule inhibitor for the BRD4 bromodomains.
T1906 Molibresib GSK 525762A (I-BET 762) is an inhibitor of BET proteins (IC50: about 35 nM).
T19608 Zinc sulfate heptahydrate Zinc sulfate heptahydrate is a dietary supplement used for zinc deficiency and to prevent the condition in those at high risk.
T19618 (R)-(-)-JQ1 Enantiomer (R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 is a BET bromodomain inhibitor, acting on BRD4(1/2)(IC50 of 77 nM/33 nM in a cell-free assay)
T1972 GSK 5959 GSK-5959 is an effective, specific and cell permeable BRPF1 bromodomain inhibitor (IC50: ~80 nM). The selectivity of GSK-5959 for BRPF1 is >100-fold over a panel of 35 other bromod
T1973 PFI4 PFI-4 is a potent and selective and cell-permeable BRPF1 bromodomain inhibitor.
T1993 J147 J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurog
T19935 XD14 XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
T2072 BET bromodomain inhibitor BET bromodomain inhibitor is a potent BET inhibitor.
T2110 (+)-JQ-1 (+)-JQ1 is a BET bromodomain inhibitor (IC50: 77 nM/33 nM for BRD4 (1/2)).
T2120 I-BET151 I-BET151 (GSK1210151A) is a specific BET inhibitor for BRD2/3/4 (IC50: 0.5/0.25/0.79 μM, in cell-free assays).
T2127 OF1 OF-1 is a potent inhibitor of BRPF1B and BRPF2 bromodomain.
T22345 INCB054329 INCB054329, a structurally distinct bromodomain and extraterminal domain (BET) inhibitor, inhibits BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2
T2237 ICG001 ICG-001 antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CREB)-binding protein (CBP) with IC50 of 3 μM, but is not the rela
T2252 UNC669 UNC669 is an effective and specific MBT (malignant brain tumor) inhibitor with IC50 of 4.2/3.1 uM for L3MBTL1/3.
T2379 UNC1215 UNC1215, an effective and specific MBT (malignant brain tumor) antagonist, binds L3MBTL3 (IC50/Kd: 40/120 nM). The selectivity of UNC1215 for L3MBTL3 is 50-fold higher versus other
T2436 GSK2801 GSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains.
T2442 CPI203 CPI-203 is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4).
T2452 C646 C646, a histone acetyltransferase inhibitor, inhibits p300 (Ki: 400 nM, in a cell-free assay).
T2480 Apabetalone RVX-208, an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease.
T3217 PF-CBP1 hydrochloride PF-CBP1 is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP).It inhibits CREBBP and p300 bromodomains with IC50 of 125 and 363 nM respectively.
T3311 GSK6853 GSK6853 is a potent, soluble, cell-active, and highly selective inhibitor of the BRPF1 bromodomain.
T3504 AZD5153 6-Hydroxy-2-naphthoic acid AZD5153 (6-​Hydroxy-​2-​naphthoic Acid) is a potent triazolopyridazine-based Bromodomain (BRD4) and Extraterminal (BET) inhibitor used in cancer treatments.
T3697 3,6'-Disinapoyl sucrose 3, 6'-Disinapoyl sucrose shows the neuroprotective effect and antidepressive activity in rats.
T3712 Mivebresib Mivebresib, also known as ABBV-075, is a potent BET inhibitor (bromodomain (BRD)-containing protein) with potential antineoplastic activity. Upon administration, the bromodomain in
T3969 I-CBP112 I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor targeting the CBP/p300 bromodomains.
T3973 PF-CBP1 PF-CBP1 HCl is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP). It inhibits CREBBP (IC50: 125 nM) and p300 bromodomains (IC50: 363 nM).
T3986 SF2523 SF2523 is a highly selective and potent inhibitor.
T4012 UNC 926 hydrochloride UNC-926 inhibits L3MBTL1 (IC50: 3.9 μM). UNC-926 also exhibits a low micromolar affinity for L3MBTL3. UNC-926 inhibits binding of the 3xMBT domain to H4K20me1. It selectively and
T4247 I-CBP112 hydrochloride I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors. I-CBP112 (1 mM) has little activity against other bromodomains. I-CBP112 targets the CBP/p300
T4345 CeMMEC1 CeMMEC1 is an inhibitor of BRD4, and also has a great affinity for TAF1(IC50=0.9 μM).
T4365 FL411 FL-411 is a potent and selective BRD4 inhibitor with an IC50 of 0.43±0.09 μM for BRD4.
T4495 dBET1 dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.
T4697 ABBV744 ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2/3/4. It is used in the research on inflammatory diseases, cancer, and AIDS.
T5130 dBET6 dBET6 is a selective and cell-permeable degrader of BET based on PROTAC (IC50: 14 nM). It has antitumor activity.
T5318 CREB inhibitor 666-15 is a potent and selective CREB inhibitor (IC50: 81 nM).
T5362 Y06036 Y06036, a potent and selective BET inhibitor, can bind to the BRD4(1) bromodomain (Kd: 82 nM).
T5417 INCB057643 INCB057643 is a potent, selective and orally bioavailable BET inhibitor.
T5434 ARV-825 ARV-825, a heterobifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon leading to fast, efficient, and prolonged degradation of
T5435 ARV-771 ARV-771 is a potent BET degrader based on PROTAC technology with Kds of 34, 4.7, 8.3, 7.6, 9.6, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectivel
T5436 MZ 1 MZ 1 is a BRD4 protein degrader based on PROTAC technology.
T5440 Dbet57 dBET57 is heterobifunctional degrader of BRD4 based on the PROTAC technology, exhibits significant degradation of BRD4BD1 with a DC50/5h of 500 nM ,and inactive on BRD4BD2
T5442 A1874 A1874 is a nutlin-based and BRD4-degrading PROTAC which induces BRD4 degradation in cells. Effective in inhibiting many cancer cell lines proliferation.
T5443 JQ-1 carboxylic acid JQ-1 carboxylic acid is a cell-permeable BRD4 inhibitor with IC50s of 77 nM for BRD4(1) and 33 nM for BRD4(2)
T5468 YF-2 YF-2 is blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus,  CBP, PCAF, and GCN5 with EC50s of 2.75 μM, 29.04 μM and 49.31 μM ,
T5575 Cyclogalegenol Astramembrangenin (Cycloastragenol) is a triterpenoid saponin compound and a hydrolysis product of the main active ingredient in Astragalus membranaceus. Cycloastragenol (CAG) may
T6021 GSK1324726A GSK1324726A is a greatly specific inhibitor of BET family proteins for BRD2(IC50=41 nM), BRD3(IC50=31 nM), and BRD4 (IC50=22 nM).
T6026 CPI203 CPI-203 is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4).
T6032 Birabresib Birabresib is a synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic a
T6173 BI 2536 BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
T6222 PFI1 PFI-1, a specific BET (bromodomain-containing protein) inhibitor for BRD4, is with the IC50 of 0.22 μM in a cell-free assay.
T6255 Bromosporine Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.
T6389 Anacardic Acid Anacardic Acid is an effective inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases. It also has antimicrobial activity, antibacterial activity, and inhibits
T6668 SGC-CBP30 SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).
T6783 BI7273 BI-7273 is an effective, specific, BRD9 BD Inhibitor, which can infiltrate cell.
T6786 BI9564 BI-9564, a specific cell-permeable BRD9 BD inhibitor. The Kd for BRD9 is 5.9 nM, and IC50 for BET family is > 100 μM.
T6811 CPI637 CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.
T6828 ZL0420 ZL0420 is a potent and selective BRD4 inhibitor. ZL0420 reduces airway inflammation and inhibits the TLR3-dependent innate immune gene program.
T6859 I-BRD9 I-BRD9 is the first selective cellular inhibitor for BRD9 with pIC50 of 7.3.
T6939 PFI3 PFI-3 is a selective chemical inhibitor for SMARCA (2/4) (Kd = 89 nM)and PBI (5) bromodomains which may result in the delay and prevention of breast cancer.
T7264 CBP/EP300-IN-1 CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
T7297 KG-501 KG-501 is a cAMP response element-binding protein (CREB) inhibitor(IC50 : 6.89 μM).
T7856 nAS-E nAS-E is an the KIX-KID interaction and CREB-mediated gene transcription inhibitor.
T7863 Hexamethylene bisacetamide Hexamethylene bisacetamide inhibits BET Bromodomain Proteins.
T8453 UNC1079 UNC1079 is an selective L3MBTL3 domain inhibitor
T8495 Alobresib Alobresib is an inhibitor of BET bromodomain,is an antineoplastic drug candidate.
T8658 NEO2734 NEO2734 is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains).
T8774 MS7972 MS7972 is CREBBP inhibitor that blocks human p53 and CREB binding protein association. MS7972 can almost completely block this BRD interaction at 50 μM
T8778 TTK21 TTK21 is an activator of CBP/p300 histone acetyltransferase activity.
TL0007 Bisdemethoxycurcumin Bisdemethoxycurcumin (BDMC) is a natural demethoxy derivative of curcumin. It is a potent activator of macrophage phagocytosis, interacting with 1α, 25-dihydroxy vitamin D3 to sti
TP2149L NP213 NP213 is a rapidly acting synthetic antimicrobial peptide (AMP). NP213 is effective and well-tolerated in resolving nail fungal infections. NP213 has anti-fungal activities. NP213
TQ0083 NI-57 NI-57 is an inhibitor of proteins of bromodomain and plant homeodomain finger-containing (BRPF) family, with IC50s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respecti
TQ0253 PLX51107 PLX51107 is a potent and selective BET inhibitor (Kds: 1.6, 2.1, 1.7, and 5 nM for BRD2-BD1, BRD3-BD1, BRD4-BD1, and BRDT-BD1).
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。